Arterial Hypertension

The FDA has granted priority review to sotatercept, a novel activin signaling inhibitor designed to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.

Patients with rosacea, alopecia areata, psoriasis or atopic dermatitis all face an elevated risk for cardiovascular disease, according to a study.

Macitentan showed no new safety signals in patients with pulmonary arterial hypertension from two real-world datasets, according to a study published in Pulmonary Circulation.

Researchers recommended a third SARS-CoV-2 vaccination dose for liver transplant recipients and patients with cirrhosis who have a low or absent serological response.

Angiotensin-converting enzyme inhibitors in patients with systemic sclerosis and concomitant arterial hypertension demonstrate an independent risk factor for developing scleroderma renal crisis, according to data published in Arthritis Research & Therapy.

Several American and European cardiology societies issued statements to dispel misinformation circulating about an association between treatment with renin-angiotensin-aldosterone system antagonists such as ACE inhibitors and angiotensin receptor blockers and increased risk for COVID-19 and increased severity of the disease for those who have contracted COVID-19.